October 27, 2023
BioNtech Reports Preliminary Phase I/II Results of its CAR T Cell Therapy CarVAC and BNT211-01 (NEO-PTC-01) at European Society for Medical Oncology (ESMO) Conference

On 24 October 2023, BioNtech announced the preliminary results of phase I/II trial evaluating BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted CAR T cell therapy and the mRNA-based CAR T booster CarVac at ESMO conference in Madrid. BioNtech reported acceptable safety and tolerability data and first hints to efficacy in solid tumours. The CAR T